Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Jaguar Health, Inc. (JAGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series I Convertible Preferred Stock",
"Global Amendment No. 2, by and between Jaguar Health, Inc. and Iliad Research and Trading, L.P",
"Global Amendment No. 2, by and between Jaguar Health, Inc. and Uptown Capital, LLC",
"Global Amendment, by and between Jaguar Health, Inc. and Streeterville Capital, LLC",
"Global Amendment No. 2, by and between Jaguar Health, Inc. and Streeterville Capital, LLC",
"Form of Warrant",
"Exchange Agreement, by and between Jaguar Health, Inc. and Uptown Capital, LLC"
08/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/14/2023 8-K Quarterly results
Docs: "Jaguar Health Reports Second Quarter 2023 Financial Results"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/13/2023 SC 13G Fife John M. reports a
07/07/2023 8-K Quarterly results
07/03/2023 8-K Quarterly results
05/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Second Amendment to the Jaguar Health, Inc. New Employee Inducement Award Plan",
"Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635"
05/16/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/15/2023 8-K Quarterly results
Docs: "Jaguar Health Reports First Quarter 2023 Financial Results"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/11/2023 D Form D - Notice of Exempt Offering of Securities:
05/11/2023 D Form D - Notice of Exempt Offering of Securities:
05/09/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock",
"Form of Warrant",
"Form of Securities Purchase Agreement",
"Standstill Agreement",
"Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea"
04/28/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
03/24/2023 10-K Annual Report for the period ended December 31, 2022
02/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Jaguar Health Regains Compliance with Nasdaq’ s Bid Price Requirement"
02/06/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financi...
Docs: "MUTUAL TERMINATION OF LICENSE AGREEMENT",
"Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’ s 2023 Focus on Human Drug Development"
01/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/30/2022 8-K Quarterly results
12/15/2022 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
11/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/18/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/16/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/21/2022 8-K Quarterly results
10/14/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDED AND RESTATED license AND SERVICES AGREEMENT"
09/30/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy